Latest Bicalutamide Stories
TOKYO and SAN FRANCISCO, May 17, 2015 /PRNewswire/ -- Astellas Pharma Inc (TSE:4503) and Medivation, Inc (NASDAQ: MDVN) today announced data from the Phase 2 STRIVE trial comparing enzalutamide and
TOKYO and SAN FRANCISCO, April 2, 2015 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503) and Medivation, Inc.
TOKYO and SAN FRANCISCO, March 24, 2015 /PRNewswire/ -- Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc.
NORTHBROOK, Ill. and SAN FRANCISCO, March 16, 2015 /PRNewswire/ -- Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) and Medivation, Inc.
Hormonal therapies can help control advanced prostate cancer for a time.
While prostate cancer is the most common cancer in elderly Western men it also, but more rarely, strikes patients aged between 35 and 50.
Patients with castration-resistant prostate cancer treated with the androgen inhibitor abiraterone and who had high baseline hormone levels had longer overall survival compared with patients with low hormone levels.
Androgen suppression – the inhibition of testosterone and other male hormones – is a routine therapy for prostate cancer.
A new drug, MDV3100, is improving the survival rate in men with advanced prostate cancer, results of a large, phase III clinical trial show.
Homosexual men taking bicalutamide for prostate cancer were much more likely to report sexual problems during treatment than heterosexual patients.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.